Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Venetoclax Combined with Vyxeos (CPX-351) for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Next Previous
Search
Trial Profile

A Phase I Study of Venetoclax Combined with Vyxeos (CPX-351) for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine/daunorubicin (Primary) ; Venetoclax (Primary)
  • Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Acronyms V2 Trial

    • Most Recent Events

    • 12 Mar 2025 Planned End Date changed from 1 Jan 2026 to 1 Jan 2028.
    • 12 Mar 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2027.
    • 18 Apr 2023 Planned number of patients changed from 18 to 21.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top